| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3809 |
| Trial ID | NCT06323525 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ATHENA-2 CAR-T |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA-2) Therapy in Adults With Refractory/Relapsed B-cell Lymphoma |
| Year | 2024 |
| Country | China |
| Company sponsor | Chinese PLA General Hospital |
| Other ID(s) | CHN-PLAGH-BT-083 |
| Cohort 1 | |||||||||||
|
|||||||||||